Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyWPS Varicose Vein Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentWPS Health InsurancePolicy N/A

    Varicose Vein Treatments Medical Guideline

    Customize your policy alerts

    Sign up for all WPS Health Insurance policy alerts

    Know when WPS Health Insurance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs medical necessity and coverage criteria for procedures used to treat varicose veins, including ablation, phlebectomy, ligation, and sclerotherapy. Coverage varies by member benefit plan and is subject to plan terms, applicable law, and prior authorization requirements.

    Policy Summary
    PayerWPS Health Insurance
    PolicyVaricose Vein Treatments Medical Guideline
    Policy CodePolicy N/A
    Change TypeAdded criteria for VenaSeal cyanoacrylate treatment
    Effective DateOct 1, 2026
    Last ReviewSep 10, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request that identifies the requested treatment and each specific vein to be treated.
    SourceLink
    POLICY UPDATE CHANGES

    Criteria for VenaSeal cyanoacrylate treatment were added to the guideline revision history effective April 1, 2023.

    5 mmMinimum diameter for GSV, SFJ, and named principal branch veins
    4 mmMinimum diameter for the SSV
    3.5 mmMinimum diameter for perforator, tributary, or accessory veins
    3 monthsRequired conservative therapy trial
    1 day/legStandard treatment approval
    2 days/legMaximum sclerotherapy approval

    Medical Necessity and Coverage Criteria

    Coverage criteria

    Varicose vein treatments are medically necessary when <strong>all</strong> of the following criteria are met. Sclerotherapy is subject to additional criteria below.

    Treatment documentation

    • The affected leg and veins to be treated are identified in the medical record.
    • The ultrasound findings and symptoms support the requested treatment.

    VenaSeal (cyanoacrylate)

    VenaSeal (cyanoacrylate) treatment is medically necessary when the general varicose-vein treatment criteria above are met.

    ALL of the following

    • The general medical-necessity criteria for varicose-vein treatment, including the required ultrasound findings, symptoms, and conservative-therapy documentation or applicable waiver, are met.
    Policy Summary
    PayerWPS Health Insurance
    PolicyVaricose Vein Treatments Medical Guideline
    Policy CodePolicy N/A
    Change TypeAdded criteria for VenaSeal cyanoacrylate treatment
    Effective DateOct 1, 2026
    Last ReviewSep 10, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request that identifies the requested treatment and each specific vein to be treated.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaClinical Thresholds and Coding ParametersPrior Authorization and Documentation RequirementsClinical BackgroundPolicy Definitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

  1. VenaSeal (cyanoacrylate) is used to treat varicose veins within its FDA-approved indication.
  2. Post-treatment sclerotherapy

    Sclerotherapy after treatment of larger qualifying veins is medically necessary when <strong>all</strong> of the following are met.

    ALL of the following

    • Larger qualifying veins—the saphenofemoral junction, saphenopopliteal junction, GSV, or SSV—have been treated and met the applicable coverage criteria.
    • At least one month has elapsed since the previous treatment.>= 1 month
    • The individual is documented to be symptomatic.
    • A postoperative ultrasound performed at least 30 days after the initial vein procedure(s) documents size and reflux measurements for the veins for which sclerotherapy is requested, and those measurements meet the size and reflux criteria in Section I, A.1 and A.2.>= 30 days

      Another trial of conservative therapy is not required.

    Sclerotherapy as the only requested treatment

    When sclerotherapy is the only requested treatment, it is medically necessary when <strong>any one</strong> of the following circumstances applies. No prior varicose-vein treatment may have been completed on the leg for which sclerotherapy is requested.

    ANY of the following

    • ALL of the following

      • The larger veins—the saphenofemoral junction, saphenopopliteal junction, GSV, or SSV—do not meet the applicable size or reflux criteria.
      • Bleeding or ruptured varicose veins are documented and require emergent treatment.
    • Skin ulceration is present with large surrounding superficial varices requiring treatment.
    • Recurrent superficial thrombophlebitis is documented, meaning at least two episodes.>= 2 episodes

    Treatment-day limits

    Treatment-day approvals are subject to the following limits. Services exceeding the stated thresholds require Health Plan Medical Director review on a case-by-case basis.

    Standard varicose-vein treatment

    • When the applicable coverage criteria are met, one Treatment Day of Service may be approved for each leg.1 day per leg

      A Treatment Day of Service may include treatment of as many approved veins as are treated on that date, including ablations and/or stab phlebectomies.

    Sclerotherapy-specific limits

    • If more than two veins in the designated leg meet the medical-necessity criteria, two Treatment Days of Service may be approved for that leg.2 days per leg
    • If only one vein in the leg meets the applicable size and reflux criteria, only one Treatment Day of Service may be approved.1 day per leg
    • More than two sclerotherapy dates of service for an approved leg within 12 months from the start of sclerotherapy treatment are not medically necessary.> 2 dates within 12 months
    • Services exceeding the sclerotherapy date-of-service thresholds require Medical Director review on a case-by-case basis.

    Ultrasound guidance during treatment is an integral component of the procedure, except for sclerotherapy.

    Treatment of any vein less than 3.5 millimeters in size—including telangiectasias, spider veins, and reticular veins—by any method is considered cosmetic and not medically necessary.

    Treatment with Varithena® (polidocanol injectable foam 1%) for incompetent greater saphenous veins, accessory saphenous veins, or visible varicosities above and below the knee is not medically necessary. All other varicose veins treated with Varithena for non-FDA-approved indications are considered experimental, investigational, and unproven.

    The following treatments are considered experimental or investigative because insufficient peer-reviewed literature documents their effectiveness, comparative methodologies, and long-term outcomes:

    1. Photothermal sclerosis, also referred to as intense pulsed light, including PhotoDerm VL®.

    2. Transilluminated powered phlebectomy, including TriVex® and TIPP.

    3. Transdermal laser therapy.

    4. ClariVein® Occlusion Catheter (endovenous mechanochemical ablation [MOCA] or nonthermal vein ablation system).

    5. Sclerotherapy for perforating-vein incompetence or saphenous-vein incompetence.

    6. Endovenous catheter-directed chemical ablation with balloon isolation, including catheter-assisted venous sclerotherapy (KAVS catheter).

    7. Cryostripping, including cryoablation, cryofreezing, cryotherapy, and transilluminated cryosurgery.

    If a service is requested or used for a condition or diagnosis other than one listed in the Indications of Coverage, it is considered experimental or investigative.

    If a service is requested or used for a condition or diagnosis listed in the Indications of Coverage but the applicable criteria are not met, it is considered not medically necessary.

    Treatment of varicose veins is not medically necessary without documentation of failed conservative therapy, unless an applicable waiver of conservative therapy is documented under the coverage criteria.

    Treatment of asymptomatic tributary veins, also known as “high veins” or “supramelic veins,” is not medically necessary.

    Multiple dates of service in the office setting are not medically necessary unless the medical record documents the medical need for repeated visits and the Health Plan’s Medical Director approves the additional services.

    Multiple dates of service in an outpatient surgical center are considered not medically necessary.

    More than two sclerotherapy dates of service for each approved leg within 12 months from the start of sclerotherapy therapy are not medically necessary. Services exceeding this threshold require Medical Director review on a case-by-case basis.

    Clinical Thresholds and Coding Parameters

    GSV or SFJ vein diameter
    Minimum diameter5 mm or greater
    Applies toThe great (large) saphenous vein (GSV) or the saphenofemoral junction (SFJ)
    Measurement methodDuplex ultrasonography of the affected leg
    SSV vein diameter
    Minimum diameter4 mm or greater
    Applies toThe small (lesser) saphenous vein (SSV)
    Measurement methodDuplex ultrasonography of the affected leg
    Named principal branch vein diameter
    Minimum diameter5 mm or greater
    Named principal branchesPosterior accessory vein, anterior accessory vein, and cephalad extension of the small saphenous vein (vein of Giacomini)
    Measurement methodDuplex ultrasonography of the affected leg
    Perforator, tributary, or other accessory vein diameter
    Minimum diameter3.5 mm or greater
    Applies toPerforator or tributary veins and additional accessory veins not otherwise referenced as named principal branches
    Measurement methodDuplex ultrasonography of the affected leg
    Superficial-vein reflux
    Minimum reflux duration500 milliseconds (0.5 seconds) or greater
    Applies toSuperficial veins, including the GSV, SSV, and SFJ
    Measurement positionPatient standing or in reverse Trendelenburg position
    Perforator or tributary outward flow
    Minimum outward-flow duration350 milliseconds (0.35 seconds) or greater
    Applies toPerforating and tributary veins
    Measurement positionPatient standing or in reverse Trendelenburg position
    Compression stocking trial
    Compression pressureGreater than 20 mmHg
    Trial durationThree months
    Required lookback periodWithin the past six months

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Specific Prior Authorization Request

    Submit a specific prior authorization request identifying the treatment or service requested and each specific vein proposed for treatment. Include the planned treatment details and use the correct coding that satisfies applicable coding guidelines.

    Prior Authorization

    Sclerotherapy Review and Limits

    Sclerotherapy of varicose veins, particularly perforators and tributaries, may be medically necessary after qualifying treatment of larger veins or when sclerotherapy is the only treatment requested. Document the applicable qualifying circumstance, symptoms or urgent indication, and required vein size and reflux measurements.

    • After larger-vein treatment: at least one month must have elapsed; the member must be symptomatic; and postoperative ultrasound performed at least 30 days after the initial procedure must show that the requested veins meet applicable size and reflux criteria.
    • When sclerotherapy is the only requested treatment: document bleeding or ruptured varicose veins requiring emergent treatment, skin ulceration with large surrounding superficial varices, or recurrent superficial thrombophlebitis (at least two episodes), as applicable.
    • A repeat trial of conservative therapy is not required after qualifying prior treatment. For each requested vein, provide size and reflux measurements meeting the applicable criteria.
    Denial Risk

    Repeated Dates of Service

    Multiple office dates of service require documentation of the medical need for repeated visits and review and approval by the Health Plan’s Medical Director. Multiple dates of service in an outpatient surgical center are considered not medically necessary.

    • Explain why repeated visits are medically necessary.
    • Obtain Medical Director approval before requesting or billing repeated office visits.
    Step Therapy

    Conservative Therapy Before Intervention

    Before intervention, document an ineffective three-month trial of conservative therapy within the preceding six months, unless a qualifying waiver applies. The trial must include analgesic medication and fitted compression stockings providing greater than 20 mmHg compression.

    • Document the trial period, medication, stocking fit and compression level, adherence, and lack of effectiveness.
    • The trial may be waived for recurrent superficial phlebitis, CEAP Class 6 non-healing ulceration directly caused by the varicose vein, bleeding from a varicosity, or prior varicose-vein procedures in the same leg.
    Step Therapy

    Sequential Treatment Before Sclerotherapy

    Sequence sclerotherapy after treatment of qualifying larger veins when that is the applicable indication. Wait at least one month after the prior treatment, obtain postoperative ultrasound at least 30 days after the initial procedure, document persistent symptoms, and confirm that the requested veins meet size and reflux criteria.

    • The postoperative ultrasound must include size and reflux measurements for the veins requested for sclerotherapy.
    • A new conservative-therapy trial is not required after qualifying prior treatment.
    Documentation Required

    Standard Written Order

    Submit a Standard Written Order prescribed by a qualified healthcare provider concerning the member’s diagnosis.

    Documentation Required

    Clinical Records

    Submit complete clinical records supporting the requested service, including medical necessity and continued need or use when applicable. Include relevant office notes and documentation of symptoms, prior treatment, conservative therapy, and the qualifying indication.

    • Include records supporting medical necessity for the specific requested treatment and veins.
    • Include continued need or use documentation when applicable.
    Documentation Required

    Ultrasound and Procedure Location

    Provide an ultrasound report with reflux and size measurements for every vein for which treatment is requested, along with the location of the planned procedure.

    • The report may identify a vein as refluxing, incompetent, or insufficient instead of stating a reflux time when conventional criteria have been met.
    • State whether the procedure will occur in an office, outpatient surgical center, inpatient setting, or another location.
    Prior Authorization

    Request Specificity

    Make the prior authorization request sufficiently specific to identify the requested treatment or service and every specific vein proposed for treatment.

    • Do not submit a generic request for varicose-vein treatment.
    • List the individual veins and requested treatment method.
    Documentation Required

    Symptoms and Functional Impact

    Document severe and persistent pain, aching, or cramping that inhibits or interferes with mobility, activities of daily living, or occupation. This symptom requirement may be waived when previous superficial thrombophlebitis is documented.

    • Describe severity, persistence, functional limitations, and interference with ADLs or work.
    • Document previous superficial thrombophlebitis when relying on the exception.
    Step Therapy

    Conservative Therapy Documentation

    Document the required conservative-therapy trial in the six months before treatment: three months of analgesic medication and fitted compression stockings with greater than 20 mmHg compression, shown to be ineffective. Identify the dates, treatment details, fit, compression level, response, and reason for failure.

    • A waiver may apply for recurrent superficial phlebitis, CEAP Class 6 non-healing ulceration caused by the varicose vein, bleeding from a varicosity, or prior varicose-vein procedures in the same leg.
    • Do not require another conservative-therapy trial when the sclerotherapy-after-prior-treatment criteria are met.
    Denial Risk

    Unlisted Diagnosis or Condition

    Flag treatment requested or used for a condition or diagnosis not listed in the guideline’s indications of coverage as experimental or investigative.

    • Review the diagnosis against the listed indications before submitting the request.
    • Experimental or investigative treatment is not medically necessary under the guideline.
    Denial Risk

    Criteria Not Met

    Flag treatment for a listed condition when the applicable medical-necessity criteria are not satisfied. Such treatment is considered not medically necessary.

    • Check the required symptoms, conservative-therapy history or waiver, vein measurements, reflux criteria, sequencing, and treatment limits.
    • Document every criterion supporting the request before submission.
    Denial Risk

    Small or Cosmetic Veins

    Flag treatment of any vein measuring less than 3.5 mm as cosmetic and not medically necessary, regardless of treatment method. This includes telangiectasias, spider veins, and reticular veins.

    • Verify and submit size measurements for each requested vein.
    • Do not request coverage for cosmetic small-vein treatment.
    Denial Risk

    Unsupported Repeated or Asymptomatic Treatment

    Flag treatment without documentation of failed conservative therapy, unless a stated exception applies. Also flag asymptomatic tributary veins, including veins described as “high veins” or “supramelic veins.”

    • Repeated office dates also require documented medical need and Health Plan Medical Director approval.
    • Multiple dates of service in an outpatient surgical center are considered not medically necessary.
    • Document a qualifying waiver when conservative therapy was not required.
    Denial Risk

    Varithena Restrictions

    Flag Varithena (polidocanol injectable foam 1%) when requested for incompetent greater saphenous veins, accessory saphenous veins, or visible varicosities above or below the knee as not medically necessary. Other Varithena use for non-FDA-approved indications is experimental, investigational, and unproven.

    Denial Risk

    Experimental Procedures

    Flag the following procedures as experimental or investigative because the guideline cites insufficient peer-reviewed evidence on effectiveness, comparative methods, or long-term outcomes.

    • Photothermal sclerosis or intense pulsed light, including PhotoDerm VL®.
    • Transilluminated powered phlebectomy, including TriVex® and TIPP.
    • Transdermal laser therapy.
    • ClariVein® Occlusion Catheter (endovenous mechanochemical ablation/MOCA).
    • Sclerotherapy for perforating-vein incompetence or saphenous-vein incompetence.
    • Endovenous catheter-directed chemical ablation with balloon isolation, including KAVS catheter.
    • Cryostripping, including cryoablation, cryofreezing, cryotherapy, and transilluminated cryosurgery.
    Denial Risk

    Unsupported Sclerotherapy Indication

    Flag sclerotherapy requested for perforating-vein incompetence or saphenous-vein incompetence as experimental or investigative. Confirm that the requested indication is a covered sclerotherapy circumstance rather than an excluded experimental indication.

    Billing Rule

    Sclerotherapy Treatment-Day Limit

    Flag more than two sclerotherapy treatment dates of service for an approved leg within the 12-month period beginning with the start of sclerotherapy therapy as not medically necessary.

    • Up to two treatment days per leg may be approved when more than two veins in that leg meet the medical-necessity size and reflux criteria.
    • If only one vein meets the criteria, only one treatment date of service may be approved.
    • Services exceeding the threshold require Health Plan Medical Director review on a case-by-case basis.

    Clinical Background

    Varicose veins are enlarged, bulging, or twisted veins commonly caused by dysfunctional valves that allow venous reflux, or backward flow of blood, and weaken the vein walls. Conservative management may include leg elevation, symptom-relief medication, avoiding prolonged immobility, compression therapy, and weight loss. When conservative care is ineffective, treatment may eliminate sources of reflux and redirect blood flow through competent veins; common endovenous approaches include radiofrequency and laser ablation.

    Policy Definitions

    Reflux
    DefinitionRetrograde or reversed venous flow
    Measurement contextMeasured while the patient is standing or in reverse Trendelenburg position
    Guideline thresholdsAt least 500 milliseconds in superficial veins and at least 350 milliseconds of outward flow in perforator or tributary veins
    GSV
    AbbreviationGSV
    Full nameGreat saphenous vein
    Also calledLarge saphenous vein
    SSV
    AbbreviationSSV
    Full nameSmall saphenous vein
    Also calledLesser saphenous vein
    SFJ
    AbbreviationSFJ
    Full nameSaphenofemoral junction
    Guideline contextIncluded with the superficial veins for reflux measurement
    CEAP Class 6
    Clinical classCEAP Class 6
    Defining conditionNon-healing skin ulceration
    Required relationshipThe ulceration is directly resulting from the varicose vein
    Treatment Day of Service
    DefinitionA date of service during which approved treatment may be performed
    Included proceduresAblations and/or stab phlebectomies
    Treatment scopeAs many approved veins as authorized for that leg may be treated during the date of service